Theranos tests detected prostate-cancer marker in prostateless women
Around 2016, Theranos' fourth lab director, Kingshuk Das, noticed a problem. He was analyzing data from the company's diagnostic devices when he saw results from tests for prostate-specific antigen, or...
Findings from this cohort study suggest that ADT use was not associated with decreased mortality from SARS-CoV-2 infection. However, large ongoing clinical trials will provide further evidence on the role of ADT or other androgen-targeted therapies in reducing COVID-19 infection severity.
The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34740548/
High risk prostate cancer (HR-PrCa) is a subset of localized PrCa with significant potential for morbidity and mortality associated with disease recurrence and metastasis. Radiotherapy combined with Androgen Deprivation Therapy...
Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34697173/
Background/aim: To evaluate the clinical outcomes of men with prostate cancer (PCa) submitted to hydrogel spacer injection before hypofractionated radiotherapy (HRT). Patients and methods: From April 2018 to April 2020,...